NOUVEAUX COMPOSES BICYCLIQUES ET PROCEDE POUR LES PREPARER

NOUVEAUX ANALOGUES DE LA THIENAMYCINE REPRESENTES PAR LA FORMULE GENERALE I CI-APRES :(CF DESSIN DANS BOPI)OU Y ET Y REPRESENTENT UN GROUPE DETACHABLE PROTECTEUR DU RADICAL CARBONYLE, Q EST UN GROUPE ALKYLE EN C A C UN GROUPE BENZYLE SUBSTITUE, UN ATOME D'HYDROGENE OU UN ION DE METAL ALCALIN ET...

Full description

Saved in:
Bibliographic Details
Main Author KAROLY LEMPERT, GABOR DOLESCHALL, JOZSEF FETTER, GYULA HORNYAK, PETER HUSZTHY, JOZSEF NYITRAI, GYULA SIMIG, KAROLY ZAUER, TIBOR GIZUR, KALMAN HARSANYI, GYORGY FEKETE, LASZLO SZPORNY ET GYORGY HAJOS
Format Patent
LanguageFrench
Published 01.07.1983
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:NOUVEAUX ANALOGUES DE LA THIENAMYCINE REPRESENTES PAR LA FORMULE GENERALE I CI-APRES :(CF DESSIN DANS BOPI)OU Y ET Y REPRESENTENT UN GROUPE DETACHABLE PROTECTEUR DU RADICAL CARBONYLE, Q EST UN GROUPE ALKYLE EN C A C UN GROUPE BENZYLE SUBSTITUE, UN ATOME D'HYDROGENE OU UN ION DE METAL ALCALIN ET R EST UN RESIDU HYDROCARBYLE EVENTUELLEMENT SUBSTITUE, ET LEURS PROCEDES DE PREPARATION.CES NOUVEAUX COMPOSES DE FORMULE GENERALE I PEUVENT ETRE UTILISES EN THERAPEUTIQUE, PRINCIPALEMENT EN TANT QU'INHIBITEURS DE B-LACTAMASE. New thienamycin analogues of the general formula (I), wherein Y and Y represent a removable carbonyl protecting group, Q' is a C1-5 alkyl group, a substituted benzyl group, hydrogen atom or an alkali metal ion, and R'' is an optionally substituted hydrocarbyl residue, are prepared in such a way that a) a compound of the general formula (II), wherein Y and Y are as defined above and Q is a C1-5 alkyl group or a substituted benzyl group, is treated with an O-acylating agent and then with a mercaptan in the presence of a tertiary amine, and the resulting product is separated, or b) the substituted benzyl moiety of a compound of the general formula (I), wherein Q' is a substituted benzyl group and the other substituents are as defined above, is removed, and, if desired, the resulting carboxylic acid is converted into its alkali metal salt. The new compounds of the general formula (I) can be used in the therapy primarily as ???-lactamase inhibitors.
Bibliography:Application Number: FR19820021976